CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients. - Vroling L; Lind JS; de Haas RR; Verheul HM; van Hinsbergh VW; Broxterman HJ; Smit EF (British journal of cancer, 2010)